FULC

Over the past six months, Fulcrum Therapeutics has experienced several stock events. On April 27, 2026, the company reported its First Quarter 2026 earnings, showing a net loss of $18.9 million and cash of $333.3 million, with a projected cash runway into 2029. On February 24, 2026, Fulcrum announced positive 12-week results from the 20 mg dose cohort of the Phase 1b PIONEER trial in SCD and plans to initiate a potential registration-enabling trial in the second half of 2026. On December 7, 2025, Fulcrum held a virtual investor event to review new clinical data from the PIONEER trial of pociredir in Sickle Cell Disease. On October 29, 2025, Fulcrum Therapeutics reported its Third Quarter 2025 financial results, announcing encouraging results from the 12 mg dose cohort of the Phase 1b PIONEER trial of pociredir in SCD.